Skip to content
Menu

Prenetics Global Limited PRE

Full chart Compare
Set alert

Price alert · PRE

All alert types
10.31 USD -0.04 (-0.39%)

Regular-session close

10.11 -0.20 -1.94%

After hours · Nov 19, 4:36 PM ET

9.69 Day range 11.79
10.31 52-week range 26.25
YTD
-34.54%
1 year
-18.88%

5D -7.66 (-42.96%)

1012.501517.50ThuFriMonTueWed10.17
Market cap
201.19M
Revenue (ttm)
22.66M
Profit margin
-219.78%
EPS (ttm)
-3.10
Shares out
10.64M
Forward P/E
-10.10
YTD return
-34.54%
1-year return
-18.88%
Volume
821.08K
Avg volume
242.23K
Open
10.79
Previous close
10.35
Day's range
9.69 – 11.79
52-week range
10.31 – 26.25
Beta
-0.21
Price target
9.00 (-12.7%)

Key statistics

50-day average
4.80
200-day average
5.03
Enterprise value
-3.77M
Price / sales
3.05
Price / book
0.33
Revenue growth
4.30%
Total cash
63.89M
Total debt
2.36M
Return on equity
-21.67%
Short % of float
0.37%

Fundamental scorecard

8 of 25 checks passed on PRE’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Financials — quick view

All financials
PRE Revenue — quarterly 46.49M
PRE Net income — quarterly -8.98M
PRE EPS — quarterly -0.52

Earnings

PRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 27, 2024Sep 1, 20240.00-0.84——
Oct 7, 2024Jun 1, 20240.00-0.88——
Oct 7, 2024Jun 1, 20240.00———
Jun 18, 2024Mar 1, 20240.00-0.38——
Jun 18, 2024Mar 1, 20240.00———
Apr 1, 2024Dec 1, 20230.00-0.52——

Upgrades / downgrades

PRE analyst upgrades and downgrades
DateFirmActionFromTo
Dec 4, 2024Cantor FitzgeraldreitOverweightOverweight
Apr 4, 2024Cantor FitzgeraldmainOverweightOverweight

About Prenetics Global Limited

Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.

Sector
Healthcare
Industry
Diagnostics & Research
Country
Hong Kong

News

Your note

Sign in to keep a note on PRE — it syncs with the Stock Master app.

Institution ownership

PRE institution ownership
Holder% heldSharesValueReported
Prudential PLC4.03%427,9632.42MSep 29, 2024
Aspex Management (HK) Ltd3.26%346,1501.96MSep 29, 2024
Nomura Holdings Inc.3.04%322,9521.83MSep 29, 2024
UBS Group AG0.12%12,47770.55KSep 29, 2024
Morgan Stanley0.02%2,37413.42KSep 29, 2024
Aspire Private Capital, LLC0.00%114644Sep 29, 2024

Fund ownership

PRE fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.06%6,51436.83KOct 30, 2024